Academic Health Unit, Education and Health Center, Federal University of Campina Grande, Cuité, Brazil.
Med Mycol. 2021 Apr 6;59(4):313-326. doi: 10.1093/mmy/myaa114.
Dermatophytoses are inflammatory cutaneous mycoses caused by dermatophyte fungi of the genera Trichophyton, Microsporum, and Epidermophyton that affect both immunocompetent and immunocompromised individuals. With therapeutic failure, dermatophytoses can become chronic and recurrent. This is partly due to their ability to develop biofilms, microbial communities involved in a polymeric matrix attached to biotic or abiotic surfaces, contributing to fungal resistance. This review presents evidence accumulated in recent years on antidermatophyte biofilm activity. The following databases were used: Web of Science, Medline/PubMed (via the National Library of Medicine), Embase, and Scopus. Original articles published between 2011 and 2020, emphasizing the antifungal activity of conventional and new drugs against dermatophyte biofilms were eligible. A total of 11 articles met the inclusion criteria and were reviewed - the studies used in vitro and ex vivo (fragments of nails and hair) experimental models. The articles focused on reports of antibiofilm activity for conventional antifungals, natural drugs, and new therapeutic tools. The strains reported on were T. mentagrophytes, T. rubrum, T. tonsurans, M. canis, and M. gypseum. Between the studies, the wide variability of experimental conditions in vitro and ex vivo was observed. The data suggest the need for methodological standardization (at some minimum). This review systematically presents current studies involving agents that present antibiofilm activity against dermatophytes; and an overview of the ideal in vitro and ex vivo experimental conditions to guarantee biofilm formation that may assist future research.
This review presents the current studies on the antibiofilm activities of drugs against dermatophytes and ideal experimental conditions, which might guarantee in vitro and ex vivo biofilm formation. It can be useful to examine the efficacy of new antimicrobial drugs against dermatophytes.
皮肤癣菌病是由亲角质真菌中的须癣毛癣菌属、小孢子菌属和表皮癣菌属引起的炎症性皮肤真菌病,影响免疫功能正常和免疫功能低下的个体。治疗失败时,皮肤癣菌病可能会变成慢性和复发性的。这在一定程度上是由于它们形成生物膜的能力,生物膜是一种涉及微生物群落的聚合物基质,附着在生物或非生物表面,导致真菌耐药性。本综述介绍了近年来关于抗真菌生物膜活性的证据。使用了以下数据库:Web of Science、Medline/PubMed(通过美国国立医学图书馆)、Embase 和 Scopus。符合纳入标准的是 2011 年至 2020 年期间发表的强调传统和新药抗皮肤癣菌生物膜活性的原始文章。共有 11 篇文章符合纳入标准并进行了综述 - 这些研究使用了体外和体外(指甲和头发碎片)实验模型。这些文章侧重于报告传统抗真菌药、天然药物和新治疗工具的抗生物膜活性。报告的菌株为须癣毛癣菌、红色毛癣菌、须癣毛癣菌、犬小孢子菌和石膏样小孢子菌。在这些研究中,观察到体外和体外实验条件的广泛可变性。这些数据表明需要进行方法学标准化(至少达到一些最低标准)。本综述系统地介绍了目前涉及对皮肤癣菌具有抗生物膜活性的药物的研究;并概述了保证生物膜形成的理想体外和体外实验条件,这可能有助于未来的研究。
非专业人员可根据自身需要进行翻译,以上为较为准确的译文。